This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carmella, S. G. Articles by Hecht, S. S. Search for Related Content PubMed PubMed Citation Articles by Carmella, S. G. Articles by Hecht, S. S. Related Collections Epidemiology Epidemiology: Biomarkers

Analysis of Total 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol in Smokers' Blood

The Cancer Center, University of Minnesota Minneapolis, Minnesota

Requests for reprints: Stephen S. Hecht, The Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street Southeast, Minneapolis, MN 55455. Phone: 612-624-7604; Fax: 612-626-5135. E-mail: hecht002{at}umn.edu

The sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL) is an excellent biomarker for uptake of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Although numerous studies have examined levels of total NNAL in the urine of people who use tobacco products, few have quantified this biomarker in blood, and the available methods used relatively large amounts of blood. A method is urgently needed for the analysis of total NNAL in blood, the fluid most commonly stored in molecular epidemiologic studies. We developed a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method for the analysis of total NNAL in 1-mL samples of plasma. LC-ESI-MS/MS provides both high-sensitivity and structural information supporting analyte identity. The method is practical and sensitive, with a detection limit of 8 fmol total NNAL/mL plasma. Levels of total NNAL averaged 42 ± 22 (SD) and ranged 1.7 to 88 fmol/mL plasma in 16 smokers; NNAL was not detected in the plasma of five nonsmokers. These results show that total NNAL can readily be quantified in 1-mL plasma samples.

This article has been cited by other articles:

				S S Hecht, S G Carmella, A Edmonds, S E Murphy, I Stepanov, X Luo, and D K Hatsukami Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco Tob. Control, April 1, 2008; 17(2): 128 - 131. [Abstract] [Full Text] [PDF]

				S. S. Hecht, S. G. Carmella, S. E. Murphy, W. T. Riley, C. Le, X. Luo, M. Mooney, and D. K. Hatsukami Similar Exposure to a Tobacco-Specific Carcinogen in Smokeless Tobacco Users and Cigarette Smokers Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1567 - 1572. [Abstract] [Full Text] [PDF]

				I. Stepanov, S. S. Hecht, B. Lindgren, P. Jacob III, M. Wilson, and N. L. Benowitz Relationship of Human Toenail Nicotine, Cotinine, and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol to Levels of These Biomarkers in Plasma and Urine Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1382 - 1386. [Abstract] [Full Text] [PDF]

				S. G. Carmella, A. Yoder, and S. S. Hecht Combined Analysis of r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-Tetrahydrophenanthrene and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol in Smokers' Plasma. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1490 - 1494. [Abstract] [Full Text] [PDF]